SG11201508447TA - Expression process - Google Patents

Expression process

Info

Publication number
SG11201508447TA
SG11201508447TA SG11201508447TA SG11201508447TA SG11201508447TA SG 11201508447T A SG11201508447T A SG 11201508447TA SG 11201508447T A SG11201508447T A SG 11201508447TA SG 11201508447T A SG11201508447T A SG 11201508447TA SG 11201508447T A SG11201508447T A SG 11201508447TA
Authority
SG
Singapore
Prior art keywords
expression process
expression
Prior art date
Application number
SG11201508447TA
Other languages
English (en)
Inventor
Fay Louise Saunders
Anna Louise Dodds
Adeline Marie Geraldine Bayard
Bhupendra Vallabh Kara
Original Assignee
Fujifilm Diosynth Biotechnologies Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201308017A external-priority patent/GB201308017D0/en
Priority claimed from GB201320339A external-priority patent/GB201320339D0/en
Application filed by Fujifilm Diosynth Biotechnologies Uk Ltd filed Critical Fujifilm Diosynth Biotechnologies Uk Ltd
Publication of SG11201508447TA publication Critical patent/SG11201508447TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
SG11201508447TA 2013-05-03 2014-04-29 Expression process SG11201508447TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201308017A GB201308017D0 (en) 2013-05-03 2013-05-03 Expression process
GB201320339A GB201320339D0 (en) 2013-11-18 2013-11-18 Expression Process
PCT/GB2014/000165 WO2014177826A1 (en) 2013-05-03 2014-04-29 Expression process

Publications (1)

Publication Number Publication Date
SG11201508447TA true SG11201508447TA (en) 2015-11-27

Family

ID=50639794

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508447TA SG11201508447TA (en) 2013-05-03 2014-04-29 Expression process

Country Status (12)

Country Link
US (3) US9873891B2 (enExample)
EP (1) EP2992104B1 (enExample)
JP (1) JP6545153B2 (enExample)
KR (1) KR102180660B1 (enExample)
CN (2) CN114395584B (enExample)
BR (1) BR112015027373A2 (enExample)
CA (1) CA2910877C (enExample)
DK (1) DK2992104T3 (enExample)
ES (1) ES2732907T3 (enExample)
RU (1) RU2731717C2 (enExample)
SG (1) SG11201508447TA (enExample)
WO (1) WO2014177826A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323826A1 (en) * 2016-11-21 2018-05-23 Danmarks Tekniske Universitet Native chinese hamster ovary cell secretion signal peptides for production of recombinant polypeptides
JP7032438B2 (ja) 2017-12-11 2022-03-08 富士フイルム株式会社 動物細胞、動物細胞の製造方法および目的タンパク質の製造方法
EP3896168A4 (en) 2018-12-11 2022-03-02 FUJIFILM Corporation ANIMAL CELLS, METHODS OF PRODUCTION OF ANIMAL CELLS AND METHODS OF PRODUCTION OF TARGET PROTEIN
CN109837277A (zh) * 2019-03-01 2019-06-04 深圳生生凡非基因技术有限公司 一种cpgk嵌合型启动子、腺相关病毒载体及其应用
WO2021107123A1 (ja) 2019-11-29 2021-06-03 富士フイルム株式会社 細胞培養方法、抗体製造方法、有機酸除去方法、及び、抗体
EP4276167A1 (en) 2021-01-07 2023-11-15 FUJIFILM Corporation Cell selection method, device and device system
WO2022196710A1 (ja) 2021-03-17 2022-09-22 富士フイルム株式会社 細胞培養方法、及び有用物質の製造方法
CN112980852B (zh) * 2021-05-18 2021-08-13 北京华芢生物技术有限公司 新型冠状病毒b.1.351南非突变株rbd的基因及其应用
JP2024521784A (ja) 2021-05-27 2024-06-04 ヤンセン バイオテツク，インコーポレーテツド 前立腺がんの治療のための組成物及び方法
JPWO2023054556A1 (enExample) 2021-09-30 2023-04-06
JPWO2023112952A1 (enExample) 2021-12-15 2023-06-22
WO2023190300A1 (ja) 2022-03-28 2023-10-05 富士フイルム株式会社 生産物の生産方法、及び生産物
WO2023190829A1 (ja) 2022-03-31 2023-10-05 富士フイルム株式会社 生産物の製造方法、及び生産物
WO2023238949A1 (ja) 2022-06-10 2023-12-14 富士フイルム株式会社 細胞の作出方法、ヘテロ多量体タンパク質の製造方法、バイスペシフィック抗体の製造方法、ベクターセット、哺乳動物細胞、ｃｈｏ細胞、及び細胞プールの作出方法
JPWO2024071373A1 (enExample) 2022-09-29 2024-04-04
WO2025244971A1 (en) 2024-05-20 2025-11-27 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223766A1 (en) * 2002-04-30 2003-11-17 University Of North Carolina At Chapel Hill Secretion signal vectors
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
GB0602173D0 (en) * 2006-02-03 2006-03-15 Avecia Ltd Expression system
CN101646775B (zh) * 2006-12-28 2016-08-24 森托科尔奥索生物科技公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
KR101618767B1 (ko) * 2008-09-02 2016-05-09 한국생명공학연구원 외래단백질을 고효율로 생산하는 리더서열
CN102272160A (zh) * 2008-12-31 2011-12-07 印度血清及疫苗有限公司 抗rhd单克隆抗体
PE20160653A1 (es) 2009-03-05 2016-07-24 Abbvie Inc Proteinas de union a il-17
GB0905331D0 (en) * 2009-03-27 2009-05-13 Avecia Biolog Ltd Expression process
KR101420274B1 (ko) * 2011-06-13 2014-07-21 주식회사 종근당 Ｃｓｐ－ｂ ５＇ｓａｒ 인자를 포함하는 동물세포 발현 벡터 및 이를 이용한 재조합 단백질의 제조방법

Also Published As

Publication number Publication date
CN105392889A (zh) 2016-03-09
US11306323B2 (en) 2022-04-19
CN114395584B (zh) 2025-01-28
US20220213500A1 (en) 2022-07-07
CN114395584A (zh) 2022-04-26
RU2015151626A3 (enExample) 2018-03-20
RU2731717C2 (ru) 2020-09-08
JP6545153B2 (ja) 2019-07-17
KR102180660B1 (ko) 2020-11-19
EP2992104A1 (en) 2016-03-09
ES2732907T3 (es) 2019-11-26
CA2910877C (en) 2021-08-03
WO2014177826A1 (en) 2014-11-06
KR20160003705A (ko) 2016-01-11
US20180127777A1 (en) 2018-05-10
BR112015027373A2 (pt) 2017-08-29
EP2992104B1 (en) 2019-04-17
RU2015151626A (ru) 2017-06-08
US9873891B2 (en) 2018-01-23
JP2016517691A (ja) 2016-06-20
DK2992104T3 (da) 2019-07-15
US20160076051A1 (en) 2016-03-17
CA2910877A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
SG11201508447TA (en) Expression process
GB201321440D0 (en) Process
GB201312991D0 (en) Process
GB201307334D0 (en) Process
GB201416005D0 (en) Process
GB201421426D0 (en) Process
GB201322454D0 (en) Process
GB201318888D0 (en) Process
GB201421428D0 (en) Process
GB201401963D0 (en) Process
GB201322992D0 (en) New Process
GB201305361D0 (en) Enhanced expression
GB201401922D0 (en) Process
GB201322273D0 (en) Process
GB201320869D0 (en) Process
GB201314334D0 (en) Process
GB201307327D0 (en) Process
GB201302441D0 (en) Process
IL239449A0 (en) process
GB201415000D0 (en) Improved process
GB201316253D0 (en) Process
GB201307951D0 (en) Process
GB2520796B (en) Process
GB201323151D0 (en) Process
GB201317756D0 (en) New process